法尼醇X受体(FXR)激动剂西洛非索在原发性硬化性胆管炎患者96周开放标签扩展研究中的安全性与持续疗效
这项II期试验的96周开放标签扩展研究纳入47例非肝硬化大胆管型原发性硬化性胆管炎患者,每日给予西洛非索100 mg。96周时碱性磷酸酶中位下降8.3%(P=.066),γ-谷氨酰转移酶下降29.8%(P<.001),转氨酶亦下降,且停药4周后反弹;15例(32%)提前停药。作者认为西洛非索安全并改善肝脏生化及胆汁淤积和细胞损伤标志物。
要点
- 96周时碱性磷酸酶中位下降8.3%(P=.066),γ-谷氨酰转移酶下降29.8%(P<.001)。
- 15例(32%)提前停药,其中瘙痒5例、其他不良事件5例、受试者决定或研究者判断5例。
- 碱性磷酸酶应答(较基线下降≥20%)在合用与未合用熊去氧胆酸者中相似(29% vs 39%;P=.71)。
核心结论
- 在这项96周开放标签扩展研究中,西洛非索安全,并改善肝脏生化及胆汁淤积和细胞损伤生物标志物。
研究设计与样本
- II期研究(NCT02943460)12周盲法阶段完成后,非肝硬化大胆管型原发性硬化性胆管炎受试者经4周洗脱进入96周开放标签扩展,每日口服西洛非索100 mg。
- II期研究共纳入52例受试者,其中47例(90%)继续进入开放标签扩展阶段。
主要发现
- 开放标签扩展基线中位年龄44岁,男性60%,合并炎症性肠病60%,使用熊去氧胆酸45%。
- 开放标签扩展基线中位血清碱性磷酸酶368 U/L(IQR 277-468 U/L),γ-谷氨酰转移酶417 U/L(IQR 196-801 U/L)。
- 第96周血清碱性磷酸酶中位变化-8.3%(IQR -25.9%至11.0%;P=.066),γ-谷氨酰转移酶-29.8%(IQR -42.3%至-13.9%;P<.001),丙氨酸氨基转移酶-29.8%(IQR -43.7%至-6.6%;P=.002),天冬氨酸氨基转移酶-16.7%(IQR -35.3%至1.0%;P=.010),停药随访4周后反弹。
- 第96周血清7α-羟基-4-胆甾烯-3-酮(C4)中位下降29.8%(IQR -64.3%至-8.5%;P=.001)。
- 基线可检出血清胆汁酸的40例中,第48周(n=28)胆汁酸下降23.9%(IQR -44.4%至-0.6%;P=.006),第96周(n=26)下降25.7%(IQR -35.9%至53.7%;P=.91)。
关键数值与推荐
- 第72周细胞角蛋白18 M30下降17.3%(IQR -39.3%至8.8%;P=.018),细胞角蛋白18 M65下降43.5%(IQR -54.9%至15.3%;P=.096)。
- 第96周增强肝纤维化评分较基线绝对升高0.15单位(中位9.34 vs 9.53;P=.028)。
- 碱性磷酸酶应答(基线至第96周下降≥20%)合用熊去氧胆酸组29% vs 未合用组39%(P=.71)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is a major unmet medical need in clinical hepatology. Cilofexor is a nonsteroidal farnesoid X receptor agonist being evaluated for the treatment of PSC. Here, we describe the safety and preliminary efficacy of cilofexor in a 96-week, open-label extension (OLE) of a phase II trial. METHODS: Noncirrhotic subjects with large-duct PSC who completed the 12-week, blinded phase of a phase II study (NCT02943460) were eligible, after a 4-week washout period, for a 96-week OLE with cilofexor 100 mg daily. Safety, liver biochemistry, and serum markers of fibrosis, cellular injury, and pharmacodynamic effects of cilofexor (fibroblast growth factor 19, C4, and bile acids [BAs]) were evaluated. RESULTS: Among 52 subjects enrolled in the phase II study, 47 (90%) continued in the OLE phase (median age, 44 years; 60% male patients, 60% with inflammatory bowel disease, and 45% on ursodeoxycholic acid [UDCA]). At OLE baseline (BL), the median serum alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) were 368 U/L (interquartile range [IQR], 277-468 U/L) and 417 U/L (IQR, 196-801 U/L), respectively. Of the 47 subjects enrolled, 15 (32%) discontinued treatment prematurely (pruritus [n = 5], other adverse events [n = 5], subject decision/investigator discretion [n = 5]). At week 96, reductions in liver biochemistry parameters occurred, including serum ALP (median, -8.3% [IQR, -25.9% to 11.0%]; P = .066), GGT (-29.8% [IQR, -42.3% to -13.9%]; P < .001), alanine aminotransaminase (ALT) (-29.8% [IQR, -43.7% to -6.6%]; P = .002), and aspartate aminotransaminase (AST) (-16.7% [IQR, -35.3% to 1.0%]; P = .010), and rebounded after 4 weeks of untreated follow-up. ALP response (≥20% reduction from BL to week 96) was similar in the presence or absence of UDCA therapy (29% vs 39%; P = .71). At week 96, cilofexor treatment was associated with a significant reduction in serum 7α-hydroxy-4-cholesten-3-one (C4) (-29.8% [IQR, -64.3% to -8.5%]; P = .001). In subjects with detectable serum BAs at BL (n = 40), BAs decreased -23.9% (IQR, -44.4% to -0.6%; P = .006) at week 48 (n = 28) and -25.7% (IQR, -35.9% to 53.7%; P = .91) at week 96 (n = 26). Serum cytokeratin 18 (CK18) M30 and M65 were reduced throughout the OLE; significant reductions were observed at week 72 (CK18 M30, -17.3% [IQR, -39.3% to 8.8%]; P = .018; CK18 M65, -43.5% [IQR, -54.9% to 15.3%]; P = .096). At week 96, a small, but statistically significant absolute increase of 0.15 units in Enhanced Liver Fibrosis score was observed compared with BL (median, 9.34 vs 9.53; P = .028). CONCLUSIONS: In this 96-week OLE of a phase II study of PSC, cilofexor was safe and improved liver biochemistry and biomarkers of cholestasis and cellular injury. CLINICALTRIALS: gov identifier: NCT02943460.
引用
- Trauner M, Bowlus CL, Gulamhusein A, et al. Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC. Clin Gastroenterol Hepatol. 2022. PMID: 35934287. doi:10.1016/j.cgh.2022.07.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。